Objective  To investigate the effects of Shensong Yangxin capsule combined with metoprolol tartrate on hemodynamics, ventricular remodeling and adverse reactions in patients with heart failure complicated with ventricular arrhythmia.

Methods  Patients with heart failure complicated with ventricular arrhythmia from January 2019 to December 2022 were selected as research subjects. According to the different medication regimens, they were divided into the control group (n=45) and the test group (n=45). Patients in the control group were treated with metoprolol tartrate tablets and patients in the test group were treated with Shensong Yangxin capsule on the basis of the treatment in the control group. The therapeutic effects of heart failure and arrhythmia, the cardiac function indexes [left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD)], ventricular remodeling indexes [matrix metalloproteinase-9 (MMP-9) and left ventricular mass index (LVMI)], and the occurrence of adverse reactions were compared between two groups.

Results  The total effective rate of arrhythmia (97.78% vs. 86.67%, P=0.049), the total effective rate of heart failure (95.56% vs. 82.22%, P=0.044) in the test group were significantly higher than those in the control group. There was no significant difference in cardiac function indexes (LVEDD, LVESD) and ventricular remodeling indexes (MMP-9, LVMI) between two groups before treatment (P>0.05). After treatment, cardiac function indexes (LVEDD, LVESD) and ventricular remodeling indexes (MMP-9, LVMI) of the two groups were both significantly reduced (P<0.05). After treatment, the indexes of cardiac function (LVEDD, LVESD) and ventricular remodeling (MMP-9, LVMI) in the test group were significantly lower than those in the control group (P<0.05).

Conclusion  Shensong Yangxin capsule combined with metoprolol tartrate can effectively improve hemodynamics and ventricular remodeling in patients with heart failure complicated with ventricular arrhythmia.

1.2020 expert consensus on the prevention and treatment of heart failure after myocardial infarction[J]. Cardiology Plus, 2021, 6(1): 4-6. DOI: 10.4103/2470- 7511.312595.

2.Zaki HA, Bashir K, Iftikhar H, et al. An Integrative comparative study between digoxin and amiodarone as an emergency treatment for patients with atrial fibrillation with evidence of heart failure: a systematic review and meta-analysis[J]. Cureus, 2022, 14(7): e26800. DOI: 10.7759/cureus.26800.

3.Mar PL, Horbal P, Chung MK, et al. From the American Heart Association Electrocardiography and Arrhythmias Committee of the Council of Clinical Cardiology. Drug interactions affecting antiarrhythmic drug use[J]. Circ Arrhythm Electrophysiol, 2022, 15(5): e007955. DOI: 10.1161/CIRCEP.121.007955.

4.Shi S, Shi J, Jia Q, et al. Efficacy and safety of ShenSong YangXin Capsule combined with antiarrhythmic drugs for atrial fibrillation: a protocol for systematic review and network meta-analysis[J]. Medicine (Baltimore), 2020, 99(38): e22367. DOI: 10.1097/MD.0000000000022367.

5.Li J, Hu D, Song X, et al. The Role of biologically active ingredients from natural drug treatments for arrhythmias in different mechanisms[J]. Biomed Res Int, 2017, 46(5): 17-20. DOI: 10.1155/2017/4615727.

6.中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心力衰竭和心肌病杂志(中英文), 2018, 2(4): 30-31. DOI: 10.3760/cma.j.issn.0253-3758.2018.10.004

7.郑筱萸. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002: 39-40.

8.刘毅, 张萱, 王青. 慢性心力衰竭患者血清BNP、MMP-9、IL-6检测的临床价值[J]. 实用检验医师杂志, 2013, 5(3): 5-9. [Liu Y, Zhang XX, Wang Q. Clinical value of serum BNP, MMP-9 and IL-6 in patients with chronic heart failure[J]. J Pract Lab Phy, 2013, 5(3): 5-9.] DOI: 10.3969/j.issn.1674- 7151.2013.03.007.

9.Amoni M, Dries E, Ingelaere S, et al. Ventricular arrhythmias in ischemic cardiomyopathy-new avenues for mechanism-guided treatment[J]. Cells, 2021, 10(10): 2629-2630. DOI: 10.3390/cells10102629.

10.Mann DL, Givertz MM, Vader JM, et al. Effect of treatment with sacubitril/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial[J]. JAMA Cardiol, 2022, 7(1): 17-25. DOI: 10.1001/jamacardio.2021.4567.

11.Maideen NMP, Rajkapoor B, Muthusamy S, et al. A review on pharmacokinetic and pharmacodynamic drug interactions of adrenergic β-blockers with clinically relevant drugs-an overview[J]. Curr Drug Metab, 2021, 22(9): 672-682. DOI: 10.2174/1389200222666210614112529.

12.Tamirisa KP, Elkayam U, Briller JE, et al. Arrhythmias in Pregnancy[J]. JACC Clin Electrophysiol. 2022, 8(1): 120-135. DOI: 10.1016/j.jacep.2021.10.004.

13.Xi YT, Yuan LY, Zeng YY, et al. Shensong Yangxin Capsules in the adjuvant treatment of stable angina pectoris: a Meta-analysis and trial sequential analysis[J]. Zhongguo Zhong Yao Za Zhi, 2019, 44(17): 3816-3824. DOI: 10.19540/j.cnki.cjcmm.20190624.503.

14.Meng T, Wang P, Ding J, et al. Global research trends on ventricular remodeling: a bibliometric analysis from 2012 to 2022[J]. Curr Probl Cardiol, 2022, 47(11): 101332. DOI: 10.1016/j.cpcardiol.2022.101332.

15.Nandi SS, Katsurada K, Sharma NM, et al. MMP9 inhibition increases autophagic flux in chronic heart failure[J]. Am J Physiol Heart Circ Physiol, 2020, 319(6): H1414-H1437. DOI: 10.1152/ajpheart.00032.2020.

16.Cohen L, Sagi I, Bigelman E, et al. Cardiac remodeling secondary to chronic volume overload is attenuated by a novel MMP9/2 blocking antibody[J]. PLoS One, 2020, 15(4): e0231202. DOI: 10.1371/journal.pone.0231202.

17.Nandi SS, Katsurada K, Sharma NM, et al. MMP9 inhibition increases autophagic flux in chronic heart failure[J]. Am J Physiol Heart Circ Physiol, 2020, 319(6): H1414-H1437. DOI: 10.1152/ajpheart.00032.2020.

18.Liao H, Chen Q, Liu L, et al. Impact of concurrent right ventricular myocardial infarction on outcomes among patients with left ventricular myocardial infarction[J]. Sci Rep, 2020, 10(1): 1736. DOI: 10.1038/s41598-020-58713-0.

19.Jaroszyński A, Schlegel TT, Mosiewicz J, et al. Heat shock protein 27 levels predict myocardial inhomogeneities in hemodialysis patients[J]. Mediators Inflamm, 2022, 19(32): 56-57. DOI: 10.1155/2022/5618867.